Safety Monitoring of Ophthalmic Biologics: A Systematic Review of Pre- and Postmarketing Safety Data-Reference-Cited by-同舟云学术

Safety Monitoring of Ophthalmic Biologics: A Systematic Review of Pre- and Postmarketing Safety Data

Published:2014-11 Issue:9 Volume:30 Page:729-751
ISSN:1080-7683
Container-title:Journal of Ocular Pharmacology and Therapeutics
language:en
Short-container-title:Journal of Ocular Pharmacology and Therapeutics

Author:

Penedones Ana¹²,Mendes Diogo¹²,Alves Carlos¹²³,Batel Marques Francisco¹²

Affiliation:

1. Centre for Health Assessment and Drug Research (CHAD), Association for Innovation and Biomedical Research on Light and Image (AIBILI), Coimbra, Portugal.

2. School of Pharmacy, University of Coimbra, Coimbra, Portugal.

3. Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Pharmacology,Ophthalmology

Link

http://www.liebertpub.com/doi/pdf/10.1089/jop.2013.0206

Reference119 articles.

1. The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology

2. Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration

3. Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders

4. Age related macular degeneration

5. Diabetic Macular Edema: Pathogenesis and Treatment

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. International Classification System for Ocular Complications of Anti-VEGF Agents in Clinical Trials;Ophthalmology;2024-06

2. Aptamer‑based therapy for targeting key mediators of cancer metastasis (Review);International Journal of Oncology;2022-04-14

3. Adverse Drug Reactions and Toxicity of the Food and Drug Administration–Approved Antisense Oligonucleotide Drugs;Drug Metabolism and Disposition;2022-02-27

4. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT;Health Technology Assessment;2021-06

5. Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study;International Journal of Retina and Vitreous;2021-03-24